The treatment of metastatic prostate carcinoma with BNCT in the ITU TRIGA MARKII reactor on rat model
Article Sidebar
Main Article Content
Abstract
Objective: The delivery of curative radiotherapy is commonly has the potential of serious side effects. These side effects still remain dose-limiting factor for external beam radiotherapy and as also curative treatment of prostate cancer (PCa). New treatment alternatives, such as BNCT, are investigated to eliminate these limitations and to improve the therapeutic efficiency of radiation on tumour cells including prostate cancer. In this study, we investigated the efficiency of BNCT application by using our novel 10B carrier that was called as 10B-DG on PCa using an in vivo mouse xenograft model.
Material and Methods: PCa bearing Copenhagen rats (CRs) were used in this experimental animal study. A total of 12 CRs at the age of 2 months were used in this experimental animal study. MAT-LyLu PCa cells were injected subcutaneously into the peritoneal cavity of rats to create PCa model. The samples were divided into 4 groups: As, control, neutron irradiated, 10B-DG and 10B-DG + neutron irradiated group. 10BDG was administrated to tumour bearing rats and rats were exposed to 8.074 gy/hr thermal and epithermal. Tumour sizes were regularly measured by microtome and PET scan along 20 days.
Results: The results have shown that the tumor growth were regressed just in 10B-DG + neutron irradiated group. In addition that, PET-CT scan results revealed that 18FDG uptake was stopped in the BNCT treated group due to metabolic inactivation of ablated tumor tisue.
Conclusion: This study revealed that BNCT treatment can be successfully performed by using our novel 10B carrier 10BDG in the management of PCa. We suppose that this novel 10B carrier can take place as a safe and effective agent in routine clinical practice of BNCT.
Downloads
Article Details
References
Barth RF, Coderre JA, Vicente MG, Blue TE. Boron neutron capture therapy of cancer: current status and future prospects. Clinical Cancer Research. 2005 Jun 1;11(11):3987-4002.
Coderre JA, Chanana AD, Joel DD, Elowitz EH, Micca PL, Nawrocky MM, Chadha M, Gebbers JO, Shady M, Peress NS, Slatkin DN. Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity. Radiation research. 1998 Feb 1;149(2):163-70.
Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiation research. 1999; 151(1):1–18.
Uusi-Simola J, Savolainen S, Kangasmaki A, Heikkinen S, Perkio J, Ramadan UA, et al. Study of the relative dose-response of BANG-3((R)) polymer gel dosimeters in epithermal neutron irradiation. Physics in Medicine and Biology. 2003;48(17):2895-906.
van Rij CM, Wilhelm AJ, Sauerwein WAG, van Loenen AC. Boron neutron capture therapy for glioblastoma multiforme. Pharmacy World & Science. 2005;27(2):92-5.
Hopewell JW, Gorlia T, Pellettieri L, Giusti V, H-Stenstam B, Skold K. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential. Applied Radiation and Isotopes. 2011;69(12):1737-40.
Barth RF, Soloway AH, Brugger RM. Boron neutron capture therapy of brain tumors: past history, current status, and future potential. Cancer investigation. 1996 Jan 1;14(6):534-50.
Chen W, Mehta SC, Lu DR. Selective boron drug delivery to brain tumors for boron neutron capture therapy. Advanced drug delivery reviews. 1997 Jul 7;26(2):231-47.
Soloway, A.H.; Tjarks, W.; Barnum, B.A.; Rong, F.; Barth, R.F.; Codognic, I.M.; Wilson, J.G. The chemistry of neutron capture therapy. Chem. Rev. 1998, 98, 1515–1562.
Barth, R.E. A critical assessment of neutron capture therapy; an overview. J. Neuroncol. 2003, 62, 1-5.
Gupta, N.; Gahbauer, R.A.; Blue, T.E.; Albetson, B. Common challenges and problems in clinical trials of boron neutron capture therapy. J. Neuroncol. 2003, 62, 197–210.
Akan Z., Ozdemir H, Oto G, Deniz S, Kacar O, Basak AS, Cakir T, Sinav HU, Demir G. Genotoxicity and Cytotoxicity of novel 10B carrier ((2R)-4,5,6-trihydroxy-2-(hydroxymethyl) tetrahydro-2H-pyran-3-yl)boronic acid. MedSci and Discovery 2014; 1(4): 96- 108.
Akan Z, Turkmen M, Cakir T, Reyhancan IA, Colak U, Okka M, et al. Modification of the radial beam port of ITU TRIGA Mark II research reactor for BNCT applications. Applied Radiation and Isotopes. 2015;99:110-6.
Akan Z, Demiroglu H, Avcibasi U, Oto G, Ozdemir H, Deniz S, Basak A. Complexion of Boric Acid with 2-Deoxy-D-glucose (DG) as a novel boron carrier for BNCT. Medical Science and Discovery. 2014; 1(3):65-71
Hsu CF, Lin SY, Peir JJ, Liao JW, Lin YC, Chou FI. Potential of using boric acid as a boron drug for boron neutron capture therapy for osteosarcoma. Applied Radiation and Isotopes. 2011 Dec 31;69(12):1782-5.
Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 2009; 73(5 suppl):S4-10.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893-917.
Perin NN. Global variation in cancer incidence and mortality. Curr. Sci. 2001; 81: 465–474.
Hudson T, Denis LJ. Europa Uomo: the European prostate cancer coalition. Recent Results Cancer Res 2007;175:267–71.
Schroder FH, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320–8.
Gosselaar C, Roobol MJ, Schroder FH. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int 2005;95(2):231–7.
Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of longterm follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126–31.
Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, et al. High dose radiation delivered by intensity-modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876–81.
Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ,HuangE, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097–105.
Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008;71:1028–33.
Barth RF, Soloway AH, Fairchild RG, Brugger RM. Boron neutron capture therapy for cancer. Realities and prospects. Cancer. 1992;70(12):2995-3007.
Takahara K, Inamoto T, Minami K, Yoshikawa Y, Takai T, Ibuki N, Hirano H, Nomi H, Kawabata S, Kiyama S, Miyatake SI. The Anti-Proliferative Effect of Boron Neutron Capture Therapy in a Prostate Cancer Xenograft Model. PloS one. 2015 Sep 1;10(9):e0136981.
Gifford I, Vreeland W, Grdanovska S, Burgett E, Kalinich J, Vergara V, Wang CK, Maimon E, Poster D, Al-Sheikhly M. Liposome-based delivery of a boron-containing cholesteryl ester for high-LET particle-induced damage of prostate cancer cells: a boron neutron capture therapy study. International journal of radiation biology. 2014 Jun 1;90(6):480-5.
Tanaka H, Sakurai Y, Suzuki M, Takata T, Masunaga S, Kinashi Y, Kashino G, Liu Y, Mitsumoto T, Yajima S, Tsutsui H. Improvement of dose distribution in phantom by using epithermal neutron source based on the Be (p, n) reaction using a 30MeV proton cyclotron accelerator. Applied Radiation and Isotopes. 2009 Jul 31;67(7):S258-61.